Evidence method
Level · gp.fundamentals.debt_to_revenue
29.98% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Sep 30, 2024
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-24-127005General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
-0.03% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-225.63% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
58.86% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-264.24% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
281.20% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
47.45% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 75.24%
- Current
- 29.98%
- Delta
- -45.27%
- Previous
- 0.38%
- Current
- -0.03%
- Delta
- -0.41%
- Previous
- -375.85%
- Current
- -225.63%
- Delta
- 150.22%
- Previous
- 92.33%
- Current
- 58.86%
- Delta
- -33.47%
- Previous
- -390.63%
- Current
- -264.24%
- Delta
- 126.39%
- Previous
- 358.54%
- Current
- 281.20%
- Delta
- -77.34%
- Previous
- 66.03%
- Current
- 47.45%
- Delta
- -18.57%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · CUE CAPEX_INTENSITY_DECREASED →Transitioned To · CUE CASH_GENERATION_INCREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_INCREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.